Clinical Trials
229 trialsA Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
Natural History Study of Patients With Neurofibromatosis Type 2
National Institutes of Health Clinical Center (CC)
Cognitive Status After Removal of Skull Base Meningioma
Ohio State University
MOMENTUM-1
RTOG Foundation, Inc.
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Ohio State University Comprehensive Cancer Center
CSF-IMR
Medical University of Warsaw
Long-Term Longitudinal QoL in Patients Undergoing EEA
Ohio State University
NEURO-SUTURE
Medical University of Warsaw
FET-BRAIN-DX
IRCCS San Raffaele
Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma
University of California, San Francisco
MEN-301
NX Development Corp
SRS-AIM
University of California, San Francisco
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Baptist Health South Florida
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
National Cancer Institute (NCI)
MIRAGE
Istituto Oncologico Veneto IRCCS
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
Heron Neutron Medical Corp.
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
NRG Oncology
INTUITT-NF2
Massachusetts General Hospital
EViDENCE-BT
University of Zurich
CoDeB-Rad
University of Nottingham
NK Cell Therapy for Malignant Solid Brain Tumors
Peking University Third Hospital
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
PROTONBIOMARKS
Centre Leon Berard
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Jazz Pharmaceuticals
A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
Massachusetts General Hospital
Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma
University of California, San Francisco
LUPARPED
Fundación de investigación HM
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
ITM11 Expanded Access Program
ITM Solucin GmbH
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Vanderbilt-Ingram Cancer Center
MiDura
Aesculap AG
GM-HES
Chiang Mai University
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
NYU Langone Health
MOLI
University Hospital Heidelberg
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
Weill Medical College of Cornell University
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Weill Medical College of Cornell University
PIVIM
Hospices Civils de Lyon
SIMPLIF-AI
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
HiPPI
Emory University
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
GT Medical Technologies, Inc.
MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment
Shengjing Hospital
3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features
Shengjing Hospital
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
Emory University
MIND
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
DEX-NEURO
University of Malaya